Outpatient Oncology Infusion Market
Report ID: SQMIG35D2467
Report ID: SQMIG35D2467
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35D2467 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
121
|Figures:
77
Global Outpatient Oncology Infusion Market size was valued at USD 22.52 Billion in 2024 and is poised to grow from USD 24.19 Billion in 2025 to USD 42.85 Billion by 2033, growing at a CAGR of 7.42% during the forecast period (2026-2033).
The outpatient oncology infusion market major catalyst behind is transitioning chemotherapy from acute care hospitals into outpatient settings, driven primarily by advances in technology (clinical advances), economical pressures (pressure for lower cost), and changes within health plans (outpatient fee-for-service reimbursement). Infusions of chemotherapy, immunotherapy & biologics take place via out-of-hospital settings referred to physician’s offices, free-standing infusion centers, or home infusions by way of IV administration, where patients do not need to be admitted to the hospital. This movement has benefits in reducing costs to patients, increasing volume throughput, making it easier for patients to receive their treatments while still maintaining appropriate levels of oversight by clinical staff. Community-based physicians and centers have been able to use advancements such as targeted therapies, subcutaneous formulations, infusion protocols conducive to outpatient, to increase their capacity to deliver outpatient services and provide access to thousands of patients throughout the United States, all within the last 20 years.
The combination of both the demographic evolution trends adding to the increasing number of people being diagnosed with cancer, resulting in increased demand for treatment, has led to rising levels of investment both for infusion hard costs (capacity) as well as technology related utilization scheduling systems being installed by infusion facilities and insurers. The growth of biologics (IV immunotherapies) and monoclonal antibodies that require IV administration will require outpatient facilities to expand their capacity; therefore, payers are negotiating for site-neutral reimbursement for infusion services that will encourage the use of outpatient infusion providers. Adoption of biosimilars and home infusion models reduces drug spend and admission rates, enabling retail and community centers to expand networks, improve margins, and partner with oncology practices to deliver coordinated, cost effective care.
How is AI Enhancing Patient Throughput In The Outpatient Oncology Infusion Market?
Artificial intelligence (AI) can enhance patient flow through outpatient oncology infusion by reducing administrative wait times through automated scheduling, intake and clinical triage, and predicting infusion duration. Many infusion centers are struggling with limited chair capacity and complex prior authorization processes, so utilizing AI tools that manage patient communication, prioritize cases and surface requisite documentation will ensure smoother patient flows. Examples in practice include agentive scheduling systems that fill cancellation spots, AI triaging of patients prior to visits, and automating prior authorizations and medication preparation to decrease wait times.
Integrating AI with electronic health records (EHRs) and pharmacy workflows will speed medication preparation further so all steps along the patient's continuum of care will be more predictable for both clinicians and patients. Canopy, May 2026, announced a partnership with Illinois Cancer Care to implement enterprise-wide oncology AI for triage, scheduling, and communication purposes. The implementation in this case will show how AI reduces front office work for providers and increases chair turnover for outpatient infusion practices to allow them to treat more patients while providing better-quality care.
Market snapshot - (2026-2033)
Global Market Size
USD 22.52 Billion
Largest Segment
Chemotherapy Infusion
Fastest Growth
Immunotherapy Infusion
Growth Rate
7.42% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global outpatient oncology infusion market is segmented by service type, cancer type, setting, payer and region. Based on service type, the market is segmented into Chemotherapy Infusion, Immunotherapy Infusion, Targeted Therapy Infusion and Supportive Care Infusions. Based on cancer type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Hematologic Cancers and Others. Based on setting, the market is segmented into Hospital-Based Outpatient, Freestanding Infusion Centers and Physician Office Infusion. Based on payer, the market is segmented into Medicare, Commercial Insurance, Medicaid and Self-Pay. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per outpatient oncology infusion market analysis, the segment of chemotherapy infusions leads the way initially due to being the primary source of treatment in an outpatient infusion environment, with a significant amount of patient volume flowing through the service, as well as investment into the infusion infrastructure. Chemotherapy remains the predominant treatment modality with clearly defined clinical protocols, broad-based prescribing familiarity and long-standing reimbursement methodologies, allowing for continued alignment of staffing, scheduling and capital around the at-home chemotherapy operational workflow. All operational efficiencies, as well as predictable utilization of chemotherapy, continue to be the basis for focus on service line prioritization and overall resource allocation for outpatient oncology infusion providers, and solidify relationships with drug manufacturers and specialty pharmacy partners.
As per outpatient oncology infusion market forecast, the segment of immunotherapy infusions is quickly becoming the fastest growing segment of the oncology infusion market; this growth is driven by an increase in the number of indications for immunotherapy, innovative new biologics and increased clinician comfort with providing outpatient immunotherapy. Continued innovation in the development of therapies and monitoring will lead to an increase in referrals being made to outpatient oncology infusion providers; thus, increasing capacity and developing/implementing new care plans allows for significant additional revenue opportunities and accelerates the overall outpatient oncology infusion market growth.
Since it is the primary source of coverage for many oncology outpatients, the Medicare segment is the largest source of revenue for oncology providers and is primarily responsible for the development of their revenue cycles and delivery models. Thus, consistent policies and defined reimbursement regulations at the Medicare level will dictate where drugs can be administered, how they are billed, how much capital will be invested in the business, and prompt providers to create their clinical operations and contracting approaches in accordance with Medicare’s coverage criteria and prior authorisation processes to guarantee predictable reimbursement, patient access and control cost pressures.
As per outpatient oncology infusion market outlook, the commercial insurance segment is entering into the most rapid growth among payers as a result of the increase in employer-sponsored health plans, varying reimbursement levels among commercial payers, and increasing access to innovative therapies. In addition, the willingness of commercial plans to reimburse for innovative outpatient administration is driving oncology providers to form partnerships with networks, optimise their coding practices and increase the number of patients they can infuse commercially.
To get detailed segments analysis, Request a Free Sample Report
The North American market has a number of structural strengths which create a strong foundation for outpatient infusion care in oncology, leading to the region's leadership in the commercialization and adoption of innovative outpatient infusion technologies. North America has a mature healthcare infrastructure that includes many concentrated specialist networks and significant financial investment from pharmaceutical and medical device companies, allowing for the early implementation of outpatient infusion care models and infusion technologies in non-hospital settings. The reimbursement landscape and engagement with private payors incentivize the migration to outpatient infusion clinics and home care for patients, while the clear regulatory environment enables the commercialization of new biologics. High levels of clinical trial activity and the strong collaboration between academic and community healthcare providers drive rapid adoption of new models of care in outpatient settings. In addition to these factors, patient preference for a convenient model of care (i.e., less time away from home, integrated digital tools for care coordination, and established capabilities to provide home infusion services), reinforces outpatient pathways and creates a competitive environment that fosters continued leadership and innovation within the region. Ongoing strategic partnerships and investments in workforce development continue to expand the capacity for outpatient infusion care.
The United States Outpatient Oncology Infusion Market is benefiting from large numbers of specialty oncology centres, an advanced home infusion infrastructure, active private payer engagement, a large pharmaceuticals presence, a substantial amount of clinical research activity, integrated digital care coordination, the growth of biosimilars and targeted therapies (which can be administered through out patients), as well as highly skilled nurses and infusion pharmacies enabling safe and effective delivery of complex regimens across the country for patients in both ambulatory and home settings.
The Outpatient Oncology Infusion Market is supported in Canada by well-coordinated networks of provincial health authorities, a supportive funding model to facilitate access to care in support of outpatient settings, an increasing number of community oncology clinics, initiatives to support patients with less travel through the use of local infusion centres, investments in specialised infusion nursing staff, partnerships between community-based clinics and academic medical centres for protocol dissemination, implementation of best-practice safety and quality protocols to ensure successful delivery of complex therapies in outpatient settings, and an ongoing commitment to equitable access for patients living in urban and rural areas.
Expansion across Europe is driven by coordinated health policy initiatives and provider strategies that prioritize outpatient pathways to improve patient convenience and optimize hospital capacity. Robust clinical expertise in oncology, established networks of regional infusion centers, and growing support for ambulatory chemotherapy from payers enable scaling of outpatient models. Integration of biosimilars and targeted biologics appropriate for ambulatory administration, combined with investments in nurse training, infusion pharmacy services, and digital care coordination, underpins operational readiness. Cross country exchange of clinical protocols and incremental regulatory alignment encourage market expansion, while patient preference for shorter hospital exposure fosters demand for community and hospital-linked outpatient infusion solutions. Private sector investment and consolidation of specialized infusion providers are accelerating service capacity, while collaboration between hospitals and community clinics drives standardized care pathways across multiple markets.
Outpatient Oncology Infusion Market in Germany is anchored by well developed hospital networks and specialized ambulatory oncology centers, supported by collaborative clinical pathways and strong infusion nursing expertise, widespread adoption of biosimilar therapies suited to outpatient delivery, integrated oncology pharmacy services, and structured reimbursement mechanisms that favor care outside inpatient wards, enabling efficient throughput, high standards of safety and quality, and steady investment in facility upgrades and workforce development initiatives.
Outpatient Oncology Infusion Market in United Kingdom shows rapid expansion driven by private provider entry, policy emphasis on ambulatory pathways, establishment of community infusion centers, strengthened infusion nursing teams, integration between hospital oncology departments and community clinics, adoption of digital care coordination, and competitive service models focused on convenience and shorter patient journeys that enable delivery of complex therapies in diverse outpatient and community settings outside inpatient wards at scale.
Outpatient Oncology Infusion Market in France is evolving through targeted initiatives to expand day hospital and community infusion capacity, growing collaboration between regional cancer centers and local clinics, pilots that test home infusion models, emphasis on standardized safety protocols, investment in infusion pharmacy capabilities, training programs for specialized nursing, and policy measures that increasingly support outpatient delivery to improve patient convenience and reduce inpatient dependence, enhancing regional access broadly nationwide.
Asia Pacific is strengthening its role through coordinated investments in ambulatory care capacity and modernization of oncology service delivery across key markets. Expansion of specialized oncology clinics, upgrading of day hospitals, and growing emphasis on home infusion enable broader outpatient adoption, supported by increased engagement from domestic and multinational pharmaceutical companies expanding biologic and supportive therapy portfolios. Governments and payers in several markets are creating incentives for decentralized care, while technology platforms for scheduling, remote monitoring, and pharmacy logistics improve operational feasibility. Workforce development programs and partnerships with academic centers cultivate clinical expertise. Cross border knowledge transfer and private sector innovation contribute to scaling ambulatory infusion models that better address accessibility and convenience for patients across diverse urban and regional settings.
Outpatient Oncology Infusion Market in Japan is supported by sophisticated hospital systems, well established day hospitals, emphasis on precision therapies suitable for outpatient administration, strong integration of infusion pharmacy services, advanced cold chain and logistics capabilities, active collaboration between academic centers and industry, focused training for infusion nursing, adoption of digital monitoring tools, and policy measures encouraging care delivery outside inpatient settings to enhance patient convenience and system efficiency nationwide.
Outpatient Oncology Infusion Market in South Korea characterized by rapid modernization, strong hospital networks expanding ambulatory services, adoption of innovative infusion technologies, collaboration between biotech firms and clinical centers, emphasis on training infusion nurses, integration of digital health platforms for scheduling and monitoring, supportive reimbursement approaches for ambulatory care in key regions, and growing home infusion initiatives that extend access to complex therapies beyond traditional inpatient settings across urban regions.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Preference For Outpatient Care
Advancements In Targeted Therapies
Reimbursement and Payment Challenges
Operational and Safety Complexities
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape is marked by rapid consolidation among national home and ambulatory infusion providers, new entrants pushing alternate site oncology delivery, and deeper partnerships with health systems that shift care out of hospitals. Mergers and acquisitions such as Option Care Health’s combination with BioScrip and PromptCare’s acquisition of Coastal Infusion Services, plus CHC partnerships exemplified by Junction Health, drive capacity expansion, network reach, and investment in tech enabled logistics.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the outpatient oncology infusion market is propelled by the migration of cancer therapy from inpatient hospitals to ambulatory settings, a key driver that reduces costs and improves access, while a second driver is rapid uptake of immunotherapies and targeted agents expanding outpatient-appropriate regimens. A restraint is fragmented reimbursement and operational safety complexities that raise administrative burden and deter investment. North America remains the dominating region due to mature infrastructure, payer engagement and home infusion capabilities. Chemotherapy infusion is the dominating segment given its foundational role in outpatient workflows and established reimbursement pathways. Providers focusing on tech-enabled scheduling and biosimilar adoption are best positioned to capture growth.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 22.52 Billion |
| Market size value in 2033 | USD 42.85 Billion |
| Growth Rate | 7.42% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Outpatient Oncology Infusion Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Outpatient Oncology Infusion Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Outpatient Oncology Infusion Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Outpatient Oncology Infusion Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Outpatient Oncology Infusion Market size was valued at USD 22.52 Billion in 2024 and is poised to grow from USD 24.19 Billion in 2025 to USD 42.85 Billion by 2033, growing at a CAGR of 7.42% during the forecast period (2026-2033).
Competitive landscape is marked by rapid consolidation among national home and ambulatory infusion providers, new entrants pushing alternate site oncology delivery, and deeper partnerships with health systems that shift care out of hospitals. Mergers and acquisitions such as Option Care Health’s combination with BioScrip and PromptCare’s acquisition of Coastal Infusion Services, plus CHC partnerships exemplified by Junction Health, drive capacity expansion, network reach, and investment in tech enabled logistics. 'US Oncology Network (McKesson)', 'Oncology Analytics', 'American Oncology Network', 'CVS Health (Coram)', 'Option Care Health', 'BioScrip (Option Care)', 'Optum Infusion Services', 'Amedisys Inc.', 'Humana (Home Solutions)', 'Gentiva Health Services', 'Integrated Oncology Network', 'Sarah Cannon Research Institute', 'Rocky Mountain Cancer Centers', 'Texas Oncology (McKesson)', 'New York Cancer & Blood Specialists', 'Compass Oncology', 'Pacific Cancer Care', 'Cancer Care Northwest', 'Arizona Oncology (US Oncology)', 'Tennessee Oncology'
The growing preference among patients and providers for outpatient settings drives expansion of outpatient oncology infusion services by emphasizing convenience, reduced travel, and shorter wait times compared with inpatient care, encouraging providers to expand capacity and offer tailored infusion schedules, while payers and employers increasingly support care models that improve patient experience and minimize disruption; this shift stimulates investment in specialized clinics, training for infusion staff, and service models that prioritize accessibility, thereby supporting broader adoption and market growth sustainably.
Telehealth Enabled Coordination: Telehealth enabled coordination is central to outpatient oncology infusion delivery, linking remote symptom monitoring, virtual consultations, and infusion scheduling to improve continuity of care. Providers use digital platforms to triage side effects, adjust supportive therapies, and engage multidisciplinary teams without requiring on site visits. This trend enhances patient convenience and adherence while enabling earlier identification of complications and more efficient resource allocation across care sites. Health systems favor interoperable platforms that integrate with electronic records and support scalable workflows effectively.
Why does North America Dominate the Global Outpatient Oncology Infusion Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
